Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

Abstract

In our trial, inhibition of PCSK9 with evolocumab on a background of statin therapy lowered LDL cholesterol levels to a median of 30 mg per deciliter (0.78 mmol per liter) and reduced the risk of cardiovascular events. These findings show that patients with atherosclerotic cardiovascular disease benefit from lowering of LDL cholesterol levels below current targets. (Funded by Amgen; FOURIER ClinicalTrials.gov number, NCT01764633 .).

Keywords

EvolocumabMedicineHazard ratioClinical endpointInternal medicinePlaceboMyocardial infarctionPCSK9Stroke (engine)AlirocumabCardiologyConfidence intervalStatinUnstable anginaGastroenterologyRandomized controlled trialCholesterolLipoprotein

Affiliated Institutions

Related Publications

Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy

Among patients with atherosclerotic cardiovascular disease and LDL cholesterol levels of less than 70 mg per deciliter (1.81 mmol per liter), there was no incremental clinical b...

2011 New England Journal of Medicine 2850 citations

Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia

Tom Sjöblom , Esko A. Nikkilä , M. H. Frick +16 more

In a randomized, double-blind five-year trial, we tested the efficacy of simultaneously elevating serum levels of high-density lipoprotein (HDL) cholesterol and lowering levels ...

1987 New England Journal of Medicine 3872 citations

Ten-Year Mortality from Cardiovascular Disease in Relation to Cholesterol Level among Men with and without Preexisting Cardiovascular Disease

Juha Pekkanen , Shai Linn , Gerardo Heiss +4 more

To determine the associations of total, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol with mortality from coronary heart disease and cardiovascul...

1990 New England Journal of Medicine 831 citations

Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

Scott M. Grundy , James I. Cleeman , C. Noel Bairey Merz +6 more

The Adult Treatment Panel III (ATP III) of the National Cholesterol Education Program issued an evidence-based set of guidelines on cholesterol management in 2001. Since the pub...

2004 Circulation 6899 citations

PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA

J Ames S Hepherd , S Tuart M. C Obbe , I An F Ord +6 more

Background. Lowering the blood cholesterol level may reduce the risk of coronary heart disease. This double-blind study was designed to determine whether the administration of p...

1995 3460 citations

Publication Info

Year: 2017
Type: letter
Volume: 376
Issue: 18
Pages: 1713-1722
Citations: 5552
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

5552

OpenAlex

Cite This

APA Style

                            
                                
                                    Marc S. Sabatine, 
                                
                                    Robert P. Giugliano, 
                                
                                    Anthony Keech
                                
                                et al.
                            
                            (2017). 
                            Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. 
                            New England Journal of Medicine
                            , 376
                            (18)
                            , 1713-1722.
                            https://doi.org/10.1056/nejmoa1615664
                        

Identifiers

DOI: 10.1056/nejmoa1615664